Microbot Medical is excited to announce that we have successfully raised $13,000,000 in our latest funding round, marking a significant milestone in our mission to advance therapeutic endoscopy. At Microbot Medical, we are dedicated to improving patient outcomes by integrating cutting-edge energy solutions into therapeutic procedures. This generous injection of capital will allow us to accelerate the development and market deployment of our revolutionary integrated electrosurgery unit, a breakthrough innovation that leverages Bipolar Radiofrequency for precise dissection and resection alongside Microwave energy for controlled ablation and coagulation.
Our state-of-the-art platform is designed to redefine Endoscopic Submucosal Dissection (ESD) procedures by enhancing both precision and safety. With our new Speedboat RS2 instrument, clinicians benefit from a Bipolar Radiofrequency cut technique that enables finely tuned dissection, while the microwave coagulation aids in delivering controlled haemostasis. The instrument’s protective hull minimizes the risk of muscle damage, and its integrated injection needle ensures the maintenance of a stable submucosal lift without the need for instrument changes. The infusion of funds will bolster our efforts in refining these features, initiating further clinical trials, and expanding our product reach into new international markets.
This funding not only validates our technological approach but also underscores our commitment to transforming therapeutic endoscopy through innovation. We are eager to leverage this support to drive continued improvements in clinical workflows, enhance patient safety, and ultimately set new standards in minimally invasive procedures. We look forward to the next chapter of our journey, where this investment will help bridge the gap between groundbreaking research and real-world clinical impact, reshaping the future of patient care in endoscopic treatments.
